Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Salt Lake City, UT
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Madison, WI
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Palm Beach, FL
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Palm Beach, FL
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Study Site
mi
from
Durham, NC
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Study Site
mi
from
Durham, NC
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
'Aiea, HI
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
'Aiea, HI
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Metairie, LA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Saint Louis, MO
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site 1
mi
from
Fort Worth, TX
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site 1
mi
from
Fort Worth, TX
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Tucson, AZ
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Beverly Hills, CA
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Pasadena, CA
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Sacramento, CA
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Winter Haven, FL
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Winter Haven, FL
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Indianapolis, IN
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Boston, MA
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Grand Rapids, MI
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Toms River, NJ
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Toms River, NJ
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Austin, TX
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Houston, TX
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Sydney,
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Sydney,
Click here to add this to my saved trials
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated:  10/19/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated: 10/19/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated:  10/19/2017
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated: 10/19/2017
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated:  10/19/2017
Cole Eye Institute, Cleveland Clinic
mi
from
Cleveland, OH
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated: 10/19/2017
Cole Eye Institute, Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated:  10/19/2017
Scheie Eye Institute, University of Pennsylvania
mi
from
Philadelphia, PA
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated: 10/19/2017
Scheie Eye Institute, University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated:  10/19/2017
Retina Foundation of the Southwest
mi
from
Dallas, TX
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated: 10/19/2017
Retina Foundation of the Southwest
mi
from
Dallas, TX
Click here to add this to my saved trials
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated:  10/19/2017
Moran Eye Center, University of Utah
mi
from
Salt Lake City, UT
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated: 10/19/2017
Moran Eye Center, University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated:  10/19/2017
Institut de la Vision
mi
from
Paris,
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease
Status: Enrolling
Updated: 10/19/2017
Institut de la Vision
mi
from
Paris,
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia
Status: Enrolling
Updated:  10/19/2017
Andover Eye Associates
mi
from
Andover, MA
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia
Status: Enrolling
Updated: 10/19/2017
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia
A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia
Status: Enrolling
Updated:  10/22/2017
Glick Eye Institute, Indiana University School of Medicine
mi
from
Indianapolis, IN
Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia
A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia
Status: Enrolling
Updated: 10/22/2017
Glick Eye Institute, Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
An Open-label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/23/2017
Call Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
An Open-label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/23/2017
Call Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated:  10/23/2017
Dishler Laser Institute
mi
from
Greenwood Village, CO
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated: 10/23/2017
Dishler Laser Institute
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated:  10/23/2017
Discover Vision Centers
mi
from
Leawood, KA
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated: 10/23/2017
Discover Vision Centers
mi
from
Leawood, KA
Click here to add this to my saved trials
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated:  10/23/2017
Vance Thompson Vision
mi
from
Sioux Falls, SD
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated: 10/23/2017
Vance Thompson Vision
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated:  10/23/2017
Slade & Baker Vision Center
mi
from
Houston, TX
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated: 10/23/2017
Slade & Baker Vision Center
mi
from
Houston, TX
Click here to add this to my saved trials
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated:  10/23/2017
Davis Duehr Dean
mi
from
Madison, WI
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism
Status: Enrolling
Updated: 10/23/2017
Davis Duehr Dean
mi
from
Madison, WI
Click here to add this to my saved trials
Lucentis for Inflammatory Macular Edema Trial
Effect of Ranibizumab on Refractory Macular Edema in Uveitis
Status: Enrolling
Updated:  10/24/2017
Proctor Foundation, UCSF
mi
from
San Francisco, CA
Lucentis for Inflammatory Macular Edema Trial
Effect of Ranibizumab on Refractory Macular Edema in Uveitis
Status: Enrolling
Updated: 10/24/2017
Proctor Foundation, UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated:  10/24/2017
University of Miami, Bascom Palmer Eye Institute
mi
from
Miami, FL
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated: 10/24/2017
University of Miami, Bascom Palmer Eye Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated:  10/24/2017
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated: 10/24/2017
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated:  10/24/2017
Oregon Health and Science University
mi
from
Portland, OR
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated: 10/24/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated:  10/24/2017
University of Tennessee / Hamilton Eye Institute
mi
from
Memphis, TN
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated: 10/24/2017
University of Tennessee / Hamilton Eye Institute
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated:  10/24/2017
Retina Foundation of the Southwest
mi
from
Dallas, TX
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated: 10/24/2017
Retina Foundation of the Southwest
mi
from
Dallas, TX
Click here to add this to my saved trials
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated:  10/24/2017
University of Utah School of Medicine, Moran Eye Center
mi
from
Salt Lake City, UT
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
Status: Enrolling
Updated: 10/24/2017
University of Utah School of Medicine, Moran Eye Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3
Status: Enrolling
Updated:  10/24/2017
University of Virginia Driving Safety Laboratory
mi
from
Charlottesville, VA
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3
Status: Enrolling
Updated: 10/24/2017
University of Virginia Driving Safety Laboratory
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
Posterior Vitreous Detachment (PVD) Assessment During Dual RVO Lucentis Evaluations (PADDLE Study)
Status: Enrolling
Updated:  10/26/2017
Barnes Retina Institute
mi
from
Saint Louis, MO
Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
Posterior Vitreous Detachment (PVD) Assessment During Dual RVO Lucentis Evaluations (PADDLE Study)
Status: Enrolling
Updated: 10/26/2017
Barnes Retina Institute
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  10/26/2017
The Retina Institute
mi
from
Saint Louis, MO
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 10/26/2017
The Retina Institute
mi
from
Saint Louis, MO
Click here to add this to my saved trials